New Zealand markets closed

Novo Nordisk A/S (NVO)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
107.08+0.44 (+0.41%)
At close: 04:00PM EST
107.63 +0.55 (+0.51%)
After hours: 07:54PM EST
Full screen
Trade prices are not sourced from all markets
Previous close106.64
Bid0.00 x 1100
Ask0.00 x 1300
Day's range106.06 - 109.43
52-week range66.59 - 115.95
Avg. volume874,900
Market cap244.208B
Beta (5Y monthly)0.26
PE ratio (TTM)35.24
EPS (TTM)3.04
Earnings dateN/A
Forward dividend & yield1.47 (1.38%)
Ex-dividend date16 Aug 2021
1y target est118.14
  • Zacks

    GSK vs. NVO: Which Stock Should Value Investors Buy Now?

    GSK vs. NVO: Which Stock Is the Better Value Option?

  • GlobeNewswire

    Novo Nordisk A/S – Share repurchase programme

    Bagsværd, Denmark, 29 November 2021 – On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 3 February 2021. Under the programm

  • GlobeNewswire

    Novo Nordisk announces impact from Volume Based Procurement for insulin in China

    Bagsværd, Denmark, 26 November 2021 – Novo Nordisk today announced that the company has received the results from the Volume Based Procurement (VBP) tender for insulin in China. The Chinese National Healthcare Security Administration has tendered insulin sold at hospitals, and Novo Nordisk has participated in the tender. All Novo Nordisk’s insulin were included in the tender except for Ryzodeg® and Xultophy®. Novo Nordisk currently expects an estimated negative impact on global sales growth of a